Key result
Ticagrelor monotherapy reduced the composite of all-cause mortality or new Q-wave myocardial infarction by 33% compared to standard therapy in PCI patients with lower white blood cell counts, but not in those with higher counts.
Why the study?
The study aimed to investigate the efficacy and safety of ticagrelor monotherapy after PCI stratified by baseline white blood cell count.
Does aspirin-free ticagrelor monotherapy reduce ischemic events compared to standard dual antiplatelet therapy in patients undergoing PCI, and is this effect modified by baseline white blood cell count?
RCT (n=14,576)
Open-label
Randomized
Yes
Does aspirin-free ticagrelor monotherapy reduce ischemic events compared to standard dual antiplatelet therapy in patients undergoing PCI, and is this effect modified by baseline white blood cell count?
Aspirin-free ticagrelor monotherapy reduces ischemic events without increasing major bleeding compared to standard DAPT in PCI patients, but this benefit is attenuated in patients with higher baseline systemic inflammation.
Answers are grounded in this paper and cite their sources.
Suggests baseline inflammation may attenuate the ischemic benefit of ticagrelor monotherapy after PCI.
AIMS: The aim of this study was to investigate the efficacy and safety of ticagrelor monotherapy in patients undergoing percutaneous coronary intervention (PCI) stratified according to the baseline white blood cell (WBC) count. METHODS AND RESULTS: This is a post hoc analysis of the GLOBAL LEADERS trial, a multi-centre, open-label, randomized all-comer trial in patients undergoing PCI, comparing the experimental strategy (23-month ticagrelor monotherapy following 1-month dual anti-platelet therapy [DAPT]) with the reference strategy (12-month aspirin monotherapy following 12-month DAPT). Patients were stratified into two WBC groups, either < or ≥median WBC count of 7.8 × 109 cells/L (lower or higher WBC group, respectively). The primary endpoint was a composite of all-cause mortality or new Q-wave myocardial infarction at 2 years. Of 14 576 patients included in the present study, 7212 patients (49.5%) were classified as the lower WBC group, who had a significantly lower risk of both ischaemic and bleeding outcomes at 2 years. At 2 years, the experimental strategy was associated with a significant lower incidence of the primary endpoint compared with the reference strategy in the lower WBC group [2.8% vs. 4.2%; hazard ratio (HR): 0.67; 95% confidence interval (CI): 0.52-0.86] but not in the higher WBC group (4.8% vs. 4.7%; HR: 1.01; 95% CI: 0.82-1.25; Pinteraction=0.013). There were no significant differences in the risks of Bleeding Academic Research Consortium type 3 or 5 bleeding between two anti-platelet strategies regardless of the WBC groups. CONCLUSION: Increased WBC counts, which may reflect degree of inflammation, at the time of index procedure may attenuate the anti-ischaemic benefits of ticagrelor monotherapy observed in patients with lower WBC counts.
No takes yet. Share an insight, caveat, or question.
Ono et al. (2020) conducted an RCT in Percutaneous coronary intervention (n=14,576). Ticagrelor monotherapy (following 1-month DAPT) vs. Standard dual anti-platelet therapy (12-month DAPT followed by aspirin) was evaluated on Composite of all-cause mortality or new Q-wave myocardial infarction at 2 years in the lower WBC group (HR 0.67, 95% CI 0.52-0.86, p=0.002). Ticagrelor monotherapy reduced the composite of all-cause mortality or new Q-wave myocardial infarction by 33% compared to standard therapy in PCI patients with lower white blood cell counts, but not in those with higher counts.
Synapse has enriched 10 related papers. Consider them for comparative context: